This distribution is similar to that observed in patients with one primary cancer, in whom pathogenic variants in BRCA1 (35.0%), BRCA2 (23.1%), and the mismatch repair genes (15.4%) accounted for almost three-quarters of deleterious mutations. The gene discussed is BRCA2; the disease is cancer.